US 12,103,967 B2
Bispecific anti-CCL2 antibodies
Jens Fischer, Penzberg (DE); Guy Georges, Penzberg (DE); Anton Jochner, Penzberg (DE); Gregor Jordan, Penzberg (DE); Hubert Kettenberger, Penzberg (DE); Joerg Moelleken, Penzberg (DE); Tilman Schlothauer, Penzberg (DE); Georg Tiefenthaler, Penzberg (DE); Valeria Runza, Penzberg (DE); Meher Majety, Penzberg (DE); Martin Schaefer, Penzberg (DE); Maria Viert, Penzberg (DE); Shu Feng, Singapore (SG); Wei Shiong Adrian Ho, Singapore (SG); Siok Wan Gan, Singapore (SG); Runyi Adeline Lam, Singapore (SG); and Michael Gertz, Basel (CH)
Assigned to Hoffmann-La Roche Inc., Little Falls, NJ (US)
Filed by Hoffmann-La Roche Inc., Little Falls, NJ (US)
Filed on Nov. 14, 2023, as Appl. No. 18/509,252.
Application 18/509,252 is a division of application No. 18/335,941, filed on Jun. 15, 2023.
Application 18/335,941 is a division of application No. 17/123,465, filed on Dec. 16, 2020, granted, now 11,739,142, issued on Aug. 29, 2023.
Claims priority of application No. 19217665 (EP), filed on Dec. 18, 2019.
Prior Publication US 2024/0117029 A1, Apr. 11, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/46 (2006.01); A61K 39/385 (2006.01); C07K 16/24 (2006.01); C12N 5/00 (2006.01); C12N 15/09 (2006.01); A61K 39/00 (2006.01); C12N 5/07 (2010.01); C12N 15/63 (2006.01)
CPC C07K 16/24 (2013.01) [A61K 39/385 (2013.01); A61K 2039/505 (2013.01); C07K 16/46 (2013.01); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01); C12N 5/06 (2013.01); C12N 15/09 (2013.01); C12N 15/63 (2013.01)] 27 Claims
 
1. An isolated bispecific antibody that specifically binds to human CCL2 comprising a first antigen-binding site that binds specifically to a first epitope on human CCL2 and a second antigen-binding site that binds to a second epitope on human CCL2, wherein
the first antigen-binding site comprises a heavy chain variable (VH) domain comprising (a) a CDR-H1 comprising the amino acid sequence SHYGXS of SEQ ID NO: 57, wherein X is I, (b) a CDR-H2 comprising the amino acid sequence GX1IX2IFX3TANYAQKFQG of SEQ ID NO: 58, wherein X1 is V, X2 is P, and X3 is H, and (c) a CDR-H3 comprising the amino acid sequence YDAHYGELDF of SEQ ID NO: 59; and a light chain variable (VL) domain comprising (d) a CDR-L1 comprising the amino acid sequence RASQHVSDAYLA of SEQ ID NO: 60; (e) a CDR-L2 comprising the amino acid sequence DASDRAE of SEQ ID NO: 61, and (f) a CDR-L3 comprising the amino acid sequence HQYIHLHSFT of SEQ ID NO: 62; and
the second antigen-binding site comprises a VH domain comprising (a) a CDR-H1 comprising the amino acid sequence HTYMH of SEQ ID NO: 76, (b) a CDR-H2 comprising the amino acid sequence RIDPXNHNTKFDPKFQG of SEQ ID NO: 77, wherein X is D, and (c) a CDR-H3 comprising the amino acid sequence GVFGFFXH of SEQ ID NO: 78, wherein X is E; and a VL domain comprising (d) a CDR-L1 comprising the amino acid sequence KAX1EDIYNRX2A of SEQ ID NO: 79, wherein X1 is F and X2 is R, (e) a CDR-L2 comprising the amino acid sequence GATSLEH of SEQ ID NO: 80, and (f) a CDR-L3 comprising the amino acid sequence QQFXSAPYT of SEQ ID NO: 81, wherein X is W.